Asset profile
REGN5459
Multispecific antibody
Evidence outlook · no controlled comparison
NCT04083534 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT04083534: This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| REGN5459: this drug | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| GR1803 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.